Navigation Links
HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications
Date:6/3/2010

Health Industries Research Companies (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on health plans’ coverage and management of specialty pharmaceuticals.

(PRWEB) June 3, 2010 -- Health Industries Research Companies (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on health plans’ coverage and management of specialty pharmaceuticals.

Adoption of percent copays for specialty medications is forecast to grow in 2011.
HIRC asked health plan executives to assess the percentage of their commercial lives covered by three types of copays — fixed, percent and no copay —for specific medications in eight specialty drug classes. While the majority of patients remain covered by fixed copays (for medications administered in the pharmacy benefit), HIRC research finds that the usage of percent copays is expected to grow to an average of 38% in 2011. This uptake is due to “growth in the price and usage of specialty medications, the overall rising cost of health care, and the poor economy,” explains Karen Lucas, Director, Specialty Pharmaceuticals Service. Ms. Lucas further comments that “the growth of percent copays, specialty tiers, and wider copay differentials will be slow and steady as many employers remain reluctant to place heavy copay burdens on their employees.”

The majority of commercial health plan members are not covered by out-of-pocket limits.
Health plan panelists were asked to indicate if their plan has out-of-pocket limits in place to cover specialty medications. The number of plans offering out-of-pocket limits in the pharmacy benefit has remained at approximately 45% of plans since 2008. Additionally, many of the plans in HIRC research that offer out-of-pocket limits also report including other pharmacy copays (e.g. oral prescription agents) within the limit. Ms. Lucas expects that “plans will continue to put out-of-pocket limits in place as plan sponsors increasingly adopt percent copays.” Notably, in spring 2010 only one-third of commercial lives represented in HIRC research are covered by out-of-pocket limits.

The Patient Copays chapter of the Specialty Pharmaceuticals Service provides insight into health plans commercial fixed and percent copay enrollment and pricing, as well as out-of-pocket limits for eight key specialty categories.

Research Methodology:
Research was conducted in January and February 2010, with 52 pharmacy and medical directors at leading health plans representing over 46 million commercial lives. Follow-up interviews were conducted with a subset of panelists. In addition to the patient copay and pricing information highlighted in this update, the following updates are included in the Specialty Pharmaceuticals Service: location of benefits coverage, formulary and utilization management trends, and physician reimbursement and specialty pharmacy provider usage.

HEALTH INDUSTRIES RESEARCH COMPANIES (HIRC) is an independent, nonpartisan organization that conducts strategic market research on trends in health care, pharmaceutical, and managed care businesses. HIRC’s benchmark studies focus on the marketing needs of pharmaceutical companies by providing research critical to the development of successful customer-focused marketing strategies.

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4082524.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. $1.8 million awarded for palliative care research to improve care of seriously ill patients
2. Basque researchers apply chemistry to restoration of paintings and dating of signatures
3. Researchers offer solutions to poisonous well-water crisis in southern Asia
4. University of Minnesota, Mayo Clinic sign research pact with Karolinska
5. American Association for Cancer Research has Record-breaking Registration at 101st Annual Meeting
6. Only 5 percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients
7. Nottingham research leads to blood test for early detection of cancer
8. McGills Orphan Drug research offers hope
9. Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness
10. U of A discovery offers promising research for spinal-cord injury treatments
11. Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... How physicians and athletic trainers assess ... researchers presenting their work at the American Orthopaedic Society for Sports Medicine’s ... the patterns of change in concussion symptom presentation, diagnostic tools used and length ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or who ... in such facilities are specially designed to accommodate patients with a wide range of ... inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of ... Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of medical ... Dr. Russell Horine serving as the clinic director and his son Dr. Lee Horine ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... passing inspections and boosting quality. , It’s known as the “CY2016 Annual FDA ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
Breaking Medicine Technology: